Document Detail

M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy.
MedLine Citation:
PMID:  22135207     Owner:  NLM     Status:  Publisher    
The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function-enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.
Paul M McKie; Tomoko Ichiki; John C Burnett
Related Documents :
8466377 - Weight loss intervention in phase 1 of the trials of hypertension prevention. the tohp ...
24564317 - Effect of body position on intra-abdominal pressures and abdominal perfusion pressures ...
7687157 - Comparison of hypertonic saline solutions and dextran in dialysis-induced hypotension.
7985667 - Lack of efficacy of angiotensin-converting enzyme inhibitors in reducing interdialytic ...
21629337 - Factors associated with blood pressure control in diabetic patients treated in nephrolo...
12381797 - The effects of range-of-motion therapy on the plantar pressures of patients with diabet...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-3
Journal Detail:
Title:  Current hypertension reports     Volume:  -     ISSN:  1534-3111     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, Rochester, MN, 55905, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ?(5) -Phospha[7]helicenes: Synthesis, Properties, and Columnar Aggregation with One-Way Chirality.
Next Document:  The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.